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Fig. 2. Angiogram shows aneurysm of inferior thyroid 
artery. 
death of a patient. For diagnosis the authors recommend 
standard radiography, sonography, and computed tomog- 
raphy scanning. For verification and therapy, superselective 
angiography with selective mbolization, if possible, is the 
method of choice. 
Ruptures of such aneurysms ay cause acute respira- 
toric failure as a result of compression ofthe trachea. Under 
these circumstances intubation or, if this is not possible, 
tracheostomy is necessary. Surgical therapy is obligatory as 
soon as the correct diagnosis is established. 
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Regarding "Lipoprotein (a) levels in peripheral 
atherosclerotic disease" 
To the Editors: 
Few controversial data are available on lipid parameters 
in patients with abdominal aortic aneurysrns (AAA) 
compared with those in patients with peripheral athero- 
sclerotic disease (PAD) or in control subjects. 
The report by Craig et al. (J VASC SURG 1995;21: 
541-2) has shown that serum lipoprotein (a) levels are 
increased in PAD and greater in patients with AAA than in 
patients with intermittent claudication. The same occurs 
for apolipoprotein B, triglycerides and conversely for 
apolipoprotein AI levels. 
During an ultrasound screening study for AAA in the 
general population, aged 65 to 75 years, we have measured 
the same lipid and lipoprotein levels in 1460 subjects with 
normal aortic size and 69 patients with AAA greater than 
29 ram. 
Total cholesterol, high-density lipoprotein (HDL)- 
cholesterol, and triglycerides were measured by means of 
enzymatic and colorimetric methods (Roche reagents) by 
use of a COBAS-MIRA S-Roche analyzer (Hoffman- 
La Roche, Basel, Switzerland), apolipoprotein AI and 
apolipoprotein B were measured by means of nephelo- 
metric method (Behring reagents, Behring nephelometer 
analyzer; Behring, L'Aquila, Italy). 
In addition, the plasmatic levels oflipoprotein (a) were 
studied during the first year in 343 subjects without AAA 
and 34 with AAA and measured by means of immunotur- 
bidimetric analysis (Incstar reagents, COBAS-MIRA 
S-Roche analyzer), already shown superimposable to the 
ELISA method) 
The error of the assay for total cholesterol, HDL- 
cholesterol, triglycerides, apolipoprotein AI, apolipopro- 
rein B ranged from 0.2% to 0.4% and the coefficient of 
variation values were 2.6, 2.5, 3.2, 2.8, and 3.0, respec- 
tively. The error of the lipoprotein (a) assay was 0.9, 
constant and independent from the level, in the interval 
ranging 5 to 40 mg/dl. 
The statistical analysis was performed by use of the 
Student t test, and significance was accepted at the 5% level. 
All data are expressed as mean + SD and summarized 
in Table I. 
The incidence of PAD was 12.9% in control subjects 
and 25.8% in patients with AAA (p < 0.001). 
Our data are partially consistent with those of Craig et 
al.; in both studies triglycerides and apolipoprotein B are 
higher, and apolipoprotein AI is lower in patients with 
AAA than in normal subjects. In addition HDL-cholesterol 
is significantly lower in our group of AAA. 
Conversely lipoprotein (a) levels, in our experience, do 
not differ in patients with or without AAA, despite our 
preliminary data in patients with AAA matched with a 
control group showed aslight but not significant difference 
between them. 2
On the other hand, two comparative studies on lipid 
and lipoprotein profiles between patients with AAA and 
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Table I. Lipoprotein levels in 1460 control subjects and in 69 patients with AAA and 
their significance 
Hematological patterns (mg/dl) 
(mg~dl) Control AAA p Values 
Cholesterol 
Mean 223.0 237.3 0.424 
SD 43.9 41.2 
HDL 
Mean 60.9 51.0 < 0.001 
SD 15.3 11.8 
Triglycerides 
Mean 129.1 148.7 0.012 
SD 62.0 82.0 
Apolipoprotein AI 
Mean 159.1 139.2 < 0.001 
SD 38.7 28.1 
Apolipoprotein B 
Mean 140.2 157.0 0,003 
SD 45.2 52.5 
Lipoprotein (a) 
Mean 11.6 12.7 0.632 
SD 12.7 14.3 
stenosing aortoiliac disease, performed by the same group, 
have revealed controversial findings; in orte report 3HDL- 
cholesterol and apolipoprotein AI were significantly lower 
in patients with AAA (p < 0.05), whereas in the other 4
HDL-cholesterol was higher (p < 0.05). Finally another 
author found higher levels of lipoprotein (a) in patients 
with AAA than in control subjects (p < 0.01)) 
These data may allow the hypothesis that lower levels 
of HDL and apolipoprotein AI in patients with AAA could 
be related more to concurrent high rate of arteriopathy in
this group than to presence of AAA alone. 
With regard to the true meaning of lipoprotein (a) 
levels in patients with PAD or AAA, we believe that more 
data and a multivariate analysis of lipoprotein parameters 
and other associated risk factors rnainly are necessary. 
Gianantonio Simoni, MA) 
Aldo Gianotti, HA9 
Clinica Chirurgica B
University of Genoa 




1. Levine DM, Parker TS, Sloan BJ. Automated measurement of 
Lp(a) by immunoturbidimetric analysis. Int J Clin Lab Res 
1992;22:173-8. 
2. Gianotti A, Simoni G, Ardia A, Biasotti C, Bachi V. Correla- 
tion between Lp(a) and aortic abdominal neurysms. Presented 
at Lipids in Medicine '92: Italy-USA Conference; May 10-12, 
1992; Bologna, Italy. 
3. McConathy WJ, Alaupovic P, Woolcock N, Laing SP, Powell 
J, Greenhalgh R. Lipids and apolipoprotein profiles in men 
with aneurysmal and stenosing aorto-iliac atherosclerosis. Eur 
J Vasc Surg 1989;3:511-4. 
4. Louwrens HD, Adamson I, Powell JT, Greenhalgh RM. Risk 
factors for atherosclerosis in men with stenosing or aneurysmal 
disease of the abdominal orta. Int Angiol 1993;12:21-4. 
5. Norrgard O, Angquist KA, Dahlen G. High concentrations of 
Lp(a) lipoprotein in serum are common among patients with 
abdominal ortic aneurysms. Int Angiol 1988;7:46-9. 
24/41/68037 
Reply 
To the Editors: 
The data of Drs. Simoni and Gianotti regarding the 
relationship between aortic aneurysm and lipid and lipo- 
protein levels were consistent with ours in most respects. 1 
There was, however, discordance with regard to lipopro- 
rein (a) levels; we found that lipoprotein (a) levels were 
significantly elevated in abdominal ortic aneurysrn (AAA), 
whereas Simoni and Gianotti reported no difference. An 
explanation for this discrepancy may be attainable with 
existing data. 
Patient selection differed between the two studies. Our 
patients were undergoing evaluation for surgical repair of 
advanced AAA. The patients with AAA studied by Drs. 
Simoni and Gianotti, however, were identified during a 
general population screening as having an abdominal aorta 
diameter greater than 29 mm. This group therefore may 
indu& subjects having both early-stage (< 50 mm) and 
late-stage (> 60 mm) 2 aneurysms. 
Lipoprotein (a) levels are known to increase as part of 
an acute phase response) ,4 If the later stages of AAA were 
associated with an inflammatory esponse, lipoprotein (a) 
levels might be expected to increase as aneurysmal disease 
advances. Thus this discrepancy in lipoprotein (a) data 
between the two studies might be explained by differences 
